KROS Keros Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1664710 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-83.4%
TTM net income YoY-195.8%
TTM EPS YoY-248.7%
Revenue 3-yr CAGR1,616.0%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-181.3%
Net margin-152.7%
FCF margin-119.4%
EBITDA margin-177.3%
Returns
ROE-12.6%
ROA-11.8%
ROIC (approx.)-389.2%
Asset turnover0.08x
Leverage & solvency
Liabilities / assets9.2%
Debt / equity0.00x
Current ratio18.14x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio-2.6%
Payout ratio—
Capex / revenue1.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $243.86M | $0 |
| R&D expense | $129.64M | $173.63M |
| SG&A expense | $46.85M | $40.75M |
| Operating income | $67.57M | -$210.83M |
| Interest expense | — | $0 |
| Pretax income | $91.90M | -$187.05M |
| Income tax | $4.88M | $300,000 |
| Net income | $87.01M | -$187.35M |
| EBITDA | $69.08M | -$209.60M |
| EPS (basic) | 2.34 | -5.00 |
| EPS (diluted) | 2.30 | -5.00 |
| Weighted avg. shares (diluted) | 37.86M | 37.44M |
| Balance sheet | ||
| Cash & equivalents | $287.42M | $561.38M |
| Receivables | $3.57M | $2.74M |
| Current assets | $315.43M | $588.89M |
| PP&E, net | $4.30M | $4.24M |
| Total assets | $338.02M | $615.89M |
| Current liabilities | $20.41M | $27.45M |
| Total liabilities | $34.89M | $44.33M |
| Shareholders' equity | $303.13M | $571.55M |
| Shares outstanding | 19.54M | 40.55M |
| Cash flow statement | ||
| Operating cash flow | $107.50M | -$160.87M |
| Capital expenditure | $1.55M | $1.93M |
| Free cash flow | $105.95M | -$162.80M |
| Investing cash flow | -$1.55M | -$1.93M |
| Financing cash flow | -$378.47M | $391.82M |
| Depreciation & amortization | $1.51M | $1.23M |
| Stock-based compensation | $28.70M | $34.87M |
| Share buybacks | $375.00M | $0 |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.